ABSTRACT
The study presents a clinical case of treating acute myeloid leukemia with an unfavorable genetic prognosis due to genotyping by high-throughput sequencing. The patient underwent related allogeneic bone marrow transplantation with targeted chemotherapy. The disease manifested itself after a new coronavirus infection. Mutations R140Q in the IDH2 gene and P799S in the DNMT3A gene were detected by high throughput sequencing. Given the unfavorable genetic prognosis, bone marrow transplantation from an HLA-compatible sibling was performed. On day 22, COVID-19 was detected, and ruxolitinib was added to the treatment. On the 25th day, hematopoiesis was restored with the preservation of clinical and hematological remission. Ten months after transplantation, a relapse was diagnosed, for which the patient started targeted therapy with 5-azacytidine with venetoclax in combination with transfusions of donor leukocytes. The second remission was achieved after the first course. The total duration of follow-up was 24 months. © Group of authors, 2022.